Author: Editor

Dr. Zeev Estrov, of MD Anderson Cancer Center, discusses fatigue in CLL patients including findings from ongoing research on JAK2 inhibitors and the encouraging news regarding reported symptom improvements. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Breast Cancer Index (BCI) validation studies included both women treated with aromatase inhibitors (AI) and women treated with tamoxifen (Tam). The three validation studies included patients treated with Tam only (Stockholm), either anastrozole or Tam (ATAC), and Tam with a transition to letrozole (MA.17). For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

As part of our coverage of the 2015 American Society of Hematology annual meeting, myeloma expert Dr. Paul Richardson joined Patient Power to discuss this years approvals for the treatment of multiple myeloma, which includes seven total agents. Dr. Richardson reviews each of the treatments and shares how these new therapies work and how they impact multiple myeloma survival. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power founder Andrew Schorr led an expert panel as they reviewed CLL news from the 2015 American Society of Hematology (ASH) meeting in Orlando. Watch as Drs. John Gribben, Constantine Tam and William Wierda explore the full gamut of developing treatment approaches. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

As part of our coverage from the 2015 American Society of Hematology (ASH), a panel of MPN experts including Dr. Laura Michaelis, Dr. Ruben Mesa, Dr. Bart Scott and our own Andrew Schorr gathered to discuss the latest news and research in myeloproliferative neoplasms (MPNs). The experts discussed the changing treatment landscape in the field, their individualized approaches to treating MPN patients, and shared encouraging perspectives about current and future developing research. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naval Daver of MD Anderson Cancer Center speaks candidly regarding the future of myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) research and treatment. Dr. Daver discusses the increasing value of genetic analysis as well as the push to find new drugs to defeat markers and mutations. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the European Cancer Congress (ECC) 2015, Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of IMvigor 210, a multicentre, phase 2 clinical trial that was designed to evaluate the efficacy and safety of atezolizumab, an anti-PD-L1 antibody, in patients with locally-advanced or metastatic urothelial carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rachael Crayton, Oncology Specialist Nurse from Central Manchester NHS Foundation Trust, Manchester, UK, discusses the key themes from a networking exercise with cancer survivorship programmes in the UK and USA that may be used to enhance these services for patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Patient Power founder Andrew Schorr talks with MPN expert Dr. Srdan Verstovsek to reflect on the final days of the 2015 American Society of Hematology (ASH) meeting. Andrew and Dr. Verstovsek discuss the importance of a second opinion and specialized care. Learn why Dr. Verstovsek is excited about evolving research and the advances and hope of the near future. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Watch coverage from the 2015 American Society of Hematology (ASH) meeting with myeloma expert Dr. Robert Orlowski from MD Anderson Cancer Center as he joined Patient Power to answer questions from Patient Power community members. Dr. Orlowski answered a variety of questions and shared his thoughts on the latest news and research being shared at this years meeting. This program is sponsored by the Patient Empowerment Network through educational grants from Celgene, Novartis and Takeda. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Renowned CLL expert Dr. Jeff Sharman answered your questions LIVE, as we broadcasted from the 2015 American Society of Hematology (ASH) meeting. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From ASH 2015, patient advocates Andrew Schorr and Carol Preston are joined by myeloma specialist Dr. Gareth Morgan as they discuss the latest news. The panel discusses research highlights and the importance of being an informedand empoweredpatient. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient advocates and hosts Andrew Schorr and Carol Preston review the highlights from the first few days of the 2015 American Society of Hematology (ASH) meeting. Andrew and Carol are joined by Dr. Jennifer Brown, a leading CLL researcher, who shares her perspective on the role of genetics in treating CLL and her advice for getting the best care. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the American Society of Hematology (ASH) meeting in Orlando, CLL expert Dr. Jan Burger discussed the result from the RESONATE-2 trial, which studied the use of ibrutinib (Imbruvica) vs. chlorambucil in the frontline setting in patients over 65. Dr. Burger reviews the medications benefits in overall survival, progression free survival, and in response rates. Learn why Dr. Burger feels it is compelling to use ibrutinib more in the frontline setting for elderly patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the evidence requirements for the clinical development of prognostic and predictive genomic tests for individual risk stratification and adjuvant treatment selection in breast cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews This content is supported by Genomic Health, Inc.

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

In the era of molecular medicine, there is now a tool called Breast Cancer Index (BCI) to help physicians determine whether to recommend extended endocrine therapy.

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

Saad Usmani, MD Levine Cancer Institute Charlotte, NC discusses the Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015

Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses how BCR Signaling Inhibitors Extremely Active and Generally Well Tolerated from ASH 2015

Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses the Practice Changing Drugs for CLL from ASH 2015

Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses the fact that Precision Medicine Coming to Bone Marrow Transplant

Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses Pre Transplant Depression Linked to Lower Overall Survival in Post Transplant Patients

Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses a Phase 3 Randomized Trial Support High Intensity Conditioning with Myeloablative Regimens in AML

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Ixazomib Has Not Shown The Cardiotoxicity of Injectable Proteasome Inhibitors

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about how Elotuzumab Shows Benefits When Treated Early in Multiple Myeloma

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Daratumumab will Play Increasingly Important Role in Treating Multiple Myeloma According to ASH 2015 Data

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about new ASH 2015 Data That Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the importance of the RESONATE-2 Trial Results Most Likely To Move Ibrutinib to Frontline in 2016

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses Precautions and Suggestions Regarding Management of Adverse Events of BCR Signaling Inhibitors

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses MD Andersons Real World Experience With BCR signaling Inhibitors in CLL

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the nd to Chemotherapy in CLL Most Likely as Targeted and Immunotherapy Move to Frontline

Chemotherapy-induced nausea and vomiting (CINV) remains a concern for many cancer patients. At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura UK Limited, Alton, UK, discusses current approaches for optimising the management of CINV. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ruth Hammond, Vascular Access and IV Nurse Practitioner, and Clinical Practice Educator at The Royal Marsden NHS Foundation Trust, London, UK, discusses the initial findings of an audit of the experiences of wearing medical alert bands in patients with suspected neutropenic sepsis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Henry, President Elect of the UKONS, and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, explains the purpose of the UKONS, which includes promoting high standards in the nursing management and care of individuals affected by cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of the United Kingdom Oncology Nursing Society (UKONS), which is run by cancer nurses for cancer nurses, and the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the impact of the Tenovus Cancer Care Sing with Us choirs, which are open to anyone affected by cancer, on those that participate. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, explains the potential benefits of lifestyle choices, including interventions on diet and physical activity, for cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, reviews the scientific and societal challenges of drug development for the treatment of patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Entospletinib Why Its Different Than Fostamatinib

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology talks about how CLL has been Transformed in Last 5 Years and that the Hope is to Leave Chemotherapy Behind

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses ASH 2015 highlights as Bcl-2, BTK, and PI3 Inhibitors

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about how Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some Toxicity

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Ibrutinib or Idelalisib Preferred in Relapsed Patients Over Chemotherapy for CLL.

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Chlorambucil v. Ibrutinib Shows Ibrutinib Powerful in Older Patients with CLL from ASH 2015

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about the Adverse Events with Idelalisib + Rituximab May Be Autoimmune Related from ASH 2015

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses Imetelstat Pilot Study Data Released for MPN Patients

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PRM-151 Phase III Study Results in Myelofibrosis

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PERSIST-1 Phase III Study Results of Pacritinib from ASH 2015

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how the COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Real World Experience with Approved BCR Signaling Inhibitors at ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses R-CHOP With or Without Bortezomib Results at ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses the New CAR T-Cell Studies Launching Now from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Natural Therapeutic Partners for BCR Signaling Inhibitors at ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Ibrutinib in Mantle Cell Lymphoma report from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Atrial Fibrillation in Patients with CLL report from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses ABT-199 Data Released at ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Real World Experience with Ibrutinib and Idelalisib from ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Novel Nucleoside Analog Ribose Sugar in AML at ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Map Kinase Pathway P-38 in CLL

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Choosing a BCR Signaling Inhibitor in CLL from ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about ASH 2015 Highlights for Myeloma Treatments

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses the latest Advances In B-Cell Lymphoma From ASH 2015

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Second Generation B2K Inhibitors Look Promising ACP-196 & BGB-3111 at ASH 2015

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab in CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib – Rituximab Combination for Relapsed CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL at ASH 2015

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about How the Idelalisib+Ofatumumab Trial Affect Planning in CLL

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Redistribution Lymphocytosis in CLL

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Utilizing Idelalisb and Ibrutinib in CLL at ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Combining Antibody TherapyWith BTK Inhibitor in Folicular Lymphoma at ASH 2015

Press brief by Mark C. Walters, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Walters provides an update on the Northstar study of subjects treated with the LentiGlobin BB305 Drug Product. Previously reported early results in subjects with ?-thalassemia major participating in the ongoing HGB-205 and HGB-204 (Northstar) studies suggest that transplantation with autologous CD34+ cells transduced with a replication-defective, self-inactivating LentiGlobin BB305 lentiviral vector containing an engineered ?A-T87Q?globin gene (LentiGlobin BB305 Drug Product) has a positive safety profile and leads to ?A-T87Qglobin production and can lead to transfusion independence.

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Chimeric Antigen Receptor T-Cells from ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives an Update of Combining Immunotherapy with Targeted Therapies an Update from ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives and update on Checkpoint Blockade from ASH 2015

Dr. Joshua Brody, MD – @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses an update on BCR signaling inhibitors in CLL at ASH 2015

Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides an overview of a trial of allogeneic T-cells that were genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal Marsden NHS Foundation Trust, London, UK, discusses an audit of the modified UKONS telephone triage tool that has been implemented for the Acute Oncology Service at The Royal Marsden Hospital. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Join us for a provocative program format that includes point and counterpoint presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma. Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma.

Dr. Morie Gertz of the Mayo Clinic shares his overview of this year’s American Society of Hematology (ASH) meeting. He talks about Dr. Brian Durie’s discussion of three-drug treatment providing longer overall survival in newly diagnosed multiple myeloma patients versus two-drug treatment. He also discusses the recent advances in oral agents to treat multiple myeloma.

Dr. Sagar Lonial of the Winship Cancer Institute of Emory University in Atlanta, Georgia, speaks from the American Society of Hematology’s (ASH) national conference this weekend. In this video, Dr. Lonial discusses the excitement at ASH about two-drug versus three-drug treatment approaches in newly diagnosed myeloma patients.

Dr. Kenneth Anderson of the Dana-Farber Cancer Institute and Vice President of the American Society for Hematology (ASH) shares about the exciting advances being discussed at the ASH annual conference this weekend in Orlando, Florida.

Dr. Saad Usmani of the Levine Cancer Institute in Charlotte, North Carolina, gives his perspective on the treatment options for newly diagnosed as well as relapsed/refractory multiple myeloma patients, as discussed this weekend at the American Society of Hematology (ASH) annual conference in Orlando, Florida.

Dr. Meletios Dimopoulus provides an update on the Eloquent-2 Trial: A Phase 3 Randomized, Open-Label Study of elotuzumab in Combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma. Dr. Meletios Dimopoulos National and Kapodistrian University of Athens School of Medicine Athens, Greece Elotuzumab is an immunostimulatory monoclonal antibody (mAb) that recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein highly expressed by myeloma and natural killer cells. Elotuzumab has a dual mechanism of action, directly activating natural killer cells and initiating antibody-dependent cell-mediated cytotoxicity targeted against myeloma cells, with minimal effect on normal tissues. In the 2-year progression-free survival (PFS)…

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Toby Talbot, MB BS, of Royal Cornwall Hospitals NHS Trust, Truro, UK, reviews the advances in cancer immunotherapeutic approaches, highlighting the development of the anti-CTLA4 monoclonal antibody, ipilimumab, for the treatment of metastatic melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Saad Usmani reports on the clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis – a Matched Case Control Study Dr. Ashutosh Wechalekar National Amyloidosis Centre University College London London, United Kingdom Survival of patients with cardiac AL amyloidosis remains poor due to high mortality in the first 6-12 months. Rapidly effective regimes such as CyBorD are unable to overcome poor prognosis in very advanced AL amyloidosis (Venner et al and Palladini et al Leukemia 2014). The median survival of moderately advanced AL is ~60% at 2 years with CyBorD (Palladini et al Blood 2015). Last year, we reported a small series suggesting that oral…

Richard Henry, President Elect of the United Kingdom Oncology Nursing Society (UKONS), and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, discusses the overarching theme of patient safety and the subsidiary topic of haemato-oncology nursing at the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Tim Anstiss, MB, MEd, D.Occ.Med, MFSEM, of the Academy for Health Coaching, explains the concept of motivational interviewing as an approach for clinicians to communicate with patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Damian Green of Seattle Cancer Care Alliance presented at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discuses three new treatment options available for patients with multiple myeloma, and the role that clinical trials played in discovery of the new options.

Dr. Ryan Cassaday of Seattle Cancer Care Alliance presented a poster at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discusses how a treatment called hyperCVAD is making a difference for patients with ALL.

Myeloma UK provides information and support for individuals affected by multiple myeloma. At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager at Myeloma UK, Edinburgh, UK, discusses Myeloma UKs Myeloma Academy, which is an interactive learning platform designed to provide continuing professional development opportunities for multiple myeloma healthcare professionals in order to support optimal patient care. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Berman, MBBS, MRCGP, FRCP, of The Christie NHS Foundation Trust, Manchester, UK, discusses the recent progress, including the development of 5-HT3 and neurokinin-1 receptor antagonists as potential pharmacologic treatment options, in the management of chemotherapy-induced nausea and vomiting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Naughton recognizes the difference between risk of recurrence and likelihood of benefit from extended endocrine therapy, noting the two do not always correlate, as they can be based on separate biological mechanisms. A patient at high risk of recurrence does not inherently imply that patient will respond to a particular therapy.

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the ManVan initiative, which is the first dedicated mobile support service for men with prostate, testicular or penile cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Somatic Profiles – NGS Testing

MPN expert Dr. Rami S. Komrokji, Clinical Director of the Malignant Hematology Department at the Moffitt Cancer Center, shares his perspective on the future of research for myeloproliferative neoplasms, new medications and clinical trials. Dr. Komrokji explains how research, past and current, is pushing MPNs closer to becoming a chronic disease. He discusses both existing and new drug therapies and clarifies patient benefits when considering a clinical trial. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Patient Power Founder Andrew Schorr caught with patient #1 in the elotuzumab trial, Jay Carty, to get his thoughts on the approval and his perspective on the future of myeloma treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

As part of our Ask the Expert series, MPN expert Dr. Jamile Shammo of Rush University Medical Center responds to a Patient Power community members question, What do we know about ET and PV progression to myelofibrosis? Are there any ways progression can be slowed down? What research is being done in this area? Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

@OncEd Presents Dr. Barb Melosky – Best of Lung Cancer – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Winson Cheung – Best of Health Services / Survivorship – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Scott North – Best of Prostate – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Christian Kollmannsberger – Best of Non-Prostate – best of ASCO 2015 Vancouver

@OncEd Presents Dr. Stephen Chia – Best of Breast Cancer – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Michael Smylie – Best of Melanoma – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Howard Lim – Best of Non-Colorectal – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Sharlene Gill – Best of Colorectal – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Kerry Savage – Bet of Lymphoma – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Cheryl Ho – Best of Head and Neck – Best of ASCO 2015 Vancouver

@OncEd Presents Pancreatic Tumour Board – 2015

@OncEd Presents Dr. Allan Covens – BRCA Mutations in Ovarian Cancer – 2015

@OncEd Presents Dr. Scott Berry – First Line treatment of Unresectable Metastatic Colorectal Cancer – 2015

@OncEd Presents Dr. Natasha Leighl – Best of Lung Cancer – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Martina Trinkaus – Best of Hematology – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Eric Chen – Best of Head and Neck – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Kala Sridhar – Best of Non-Prostate – Best of ASCO 2015 Toronto

@OncEd Presents Dr. S̩bastien Hotte РBest of Prostate РBest of ASCO 2015 Toronto

@OncEd Presents Dr. Ron Burkes – Best of Colorectal – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Anthony Brade – Best of Radiation Oncology – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Yoo-Joung Ko – Best of Non-Colorectal – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Marcus Butler – Best of Melanoma – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Philippe Bedard – Best of Breast Cancer – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Benoit Samson – Best of Survivorship – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Jamil Asselah – Best of Breast Cancer – Best of ASCO 2015 Montreal

@OncEd Presents Dr. F̩lix Couture РBest of Colorectal РBest of ASCO 2015 Montreal

@OncEd Presents Dr. John Storring – Best of Hematology – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Benoit Samson – Best of Lung Cancer – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Fr̩d̩ric Lemay РBest of GI Cancers РBest of ASCO 2015 Montreal

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses a doctoral study that was designed to evaluate the lived experience of men who have survived at least five years after a diagnosis of prostate cancer received at or after the age of 65 years. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Joanne Upton, Skin Cancer Advanced Nurse Practitioner at The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK, discusses the development of a nurse-led, pre-treatment, telephone assessment service to address waiting times for patients receiving ipilimumab for metastatic melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager, Myeloma UK, Edinburgh, UK, discusses the role of nurses for improving the quality of life and survival of patients with multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr.Fran̤ois Patenaude РBest of Renal Cancer РBest of ASCO 2015 Montreal

@OncEd Presents Dr.Cristiano Ferrario – Best of Prostate – Best of ASCO 2015 Montreal

@OncEdPresents Dr. David Hogg – Best of Melanoma – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Jennifer Knox – Gastric, Biliary & Hepatocellular Cancers – GUGI 2015

@OncEd Presents Dr. Jean-Bernard Durand – Assessing the Impact Cardio-Toxicities Have on Patients When Continuing Chemotherapeutic Agents

@OncEd Presents Dr. Scot Dowden – Pancreatic Cancer – GUGI 2015

@OncEd Presents Dr. Nathaniel Bouganim – Best of Head and Neck – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Scott Berry – Colorectal Cancers – GUGI 2015

@OncEd Presents Dr. Eric Winquist – Bladder and Testis Cancer – GUGI 2015

@OncEd Presents Dr. Georg Bjarnason – Renal Cell Cancer – GUGI 2015

@OncEd Presents Dr. S̩bastien Hotte РCastrate Refractory Disease РGUGI 2015

@OncEd Presents Dr. Andrew Loblaw – Early Disease – GUGI 2015

@OncEd Presents Dr. Neil Fleshner – Hormone Sensitive Disease – GUGI 2015

@OncEd Presents Dr. Daniel Renouf – Individualized Treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 3 – Best of Oncology West 2015

@OncEd Presents Dr. Sharlene Gill – Individualized treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 1 – Best of Oncology West 2015

@OncEd Presents Dr. Winson Cheung – Individualized Treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 2 – Best of Oncology West 2015

@OncEd Presents Dr. Cynthia Wu – Breakfast Symposium: Blood Clots in Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Ralph Wong – Best of GI Colorectal Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Ralph Wong – Best of GI-Colorectal Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Joanna Vergidis – Best of GU Cancers – Best of Oncology West 2015

@OncEd Presents Dr. Christine Simmons – Best of Breast Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Kerry Savage – Best of Lymphoma- Best of Oncology West 2015

@OncEd Presents Dr. Barb Melosky – Best of Lung Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Jonathan Loree – Impact of Post-Operative Adjuvant Fluoropyrimidine Chemotherapy Following Pre-Operative Short Course Radiotherapy in Stage II Rectal Cancer – Best f Oncology West 2015

@OncEd Presents Dr. Richard Lee-Ying – Utility of Surveillance Following Curative Intent Resection of Metastases – Best of Oncology West 2015

@OncEd Presents Dr.Cheryl Ho – Best of Head & Neck Cancer- Best of Oncology West 2015

@OncEd Presents Dr.Sharlene Gill – Best of GI-Non-Colorectal Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Susan Ellard – Gynecological Cancer Updates – Best of Oncology West 2015

@OncEd Presents Dr. Jay Easaw – Breakfast Symposium: Blood Clots in Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Wendie Den Brok – Survival of Metastatic HR Positive/HER2 Negative, Triple Negative and HER2 Positive Breast Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Stephen Chia – Treating Advanced Breast Cancer in the Genomic Era – Best of Oncology West 2015

@OncEd Presents Dr. Philip Halloran – Identifying T Cell-Mediated Inflammation in Tissue by Molecular Phenotyping: Lessons from Kidney Transplantation – Canadian Melanoma Conference 2015

@OncEd Presents Dr. David Hogg & Dr. Xinni Song – Addressing Key Questions in immune-Oncology – Canadian Melanoma Conference 2015

@OncEd Presents Dr. David Zloty – Mohs Surgery for Melanoma and Merkel – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Heidi Wat – A Seven-Year analysis of Mitotic Rate & Sentinel Lymph Node Biopsy Status in Patients with Melanoma in Alberta From 2007-2013 – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Chlo̩ Ward РThe Rate of Missed Melanoma in Sentinel Node Negative Patients: The Ottawa Experience РCanadian Melanoma Conference 2015

@OncEd Presents Dr. Claire Temple-Oberle – Interleukin-2 for In transit Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Jeff Sosman – Treatment of Non-BRAFV600E Melanoma With Targeted Therapy – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Merrick Ross – Intralesional Therapy For Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Merrick I. Ross – The Role of Neo-Adjuvant Therapy In Resectable Advanced Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Lynne Robertson – Population Screening For Melanoma – An Alberta Trial – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Jason Rivers – Diagnostic Advances In Melanoma Detection – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Dayna Miyashiro – Immunotherapy In Stage III Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Iren Kossintseva – Melanoma Inflammatory Response Signature – Canadian Melanoma Conference 2015

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura UK Limited, Alton, UK, discusses the challenges to adherence to oral cancer therapies, as well as the role of a multidisciplinary team approach for optimising safety and adherence. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. David Hogg – Managing The Advanced Non-Melanoma Skin Cancers – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Omid Hamid – PD1 Therapy and Biomarkers for Response – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Axel Hauschild – Adjuvant Melanoma Treatment: Past, Present and Future – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Femida Gwadry-Sridhar – Do We Really Need Big Data – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Michael Davies – Clinical & Therapeutic Significance of the PI3K-AKT Pathway in Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Joel Claveau & Dr. Scott Ernst – A Practical Multi-Disciplinary Discussion of Challenging Cases in Melanoma – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Marcus Butler – Immunotherapy for All: Next Steps When Current Therapies Fail – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Marcus Butler – Immunotherapy for All: Next Steps When Current Therapies Fail – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Boris Bastian – Towards an Integrated Taxonomy of Melanocytic Neoplasms – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Eric Valli̬res РInnovation In Lung Cancer Surgery РCLCCO 2015

@OncEd Presents Dr. Glenwood Goss – Welcome From NCIC – CLCCO 2015

@OncEd Presents Dr. Sunil Verma – A National Strategy On Molecular Testing In NSCLC – CLCCO 2015

@OncEd Presents Dr. Yee Ung – A Canadian Radiation Oncologist Perspective – CLCCO 2015

@OncEd Presents Dr. Martin Reck – Lung Cancer: Today and Tomorrow – CLCCO 2015

@OncEd Presents Dr. Natasha Leigh – Third Generation EGFR TKI – CLCCO 2015

@OncEd Presents Dr. Gary Lee – Management of Malignant Pleural Effusions – CLCCO 2015

@OncEd Presents Dr. Rosalyn Juergens – Immunotherapy In NSCLC – CLCCO 2015

@OncEd Presents Dr. Laurie Gaspar – Lung Cancer Today: Maximizing the Therapeutic Ratio – CLCCO 2015

@OncEd Presents Dr. Krista Noonan – Debate: TKI in Adjuvant Setting For EGFR +VE Patients – No – CLCCO 2015

@OncEd Presents Dr. Jason Agulnik – Debate: TKI in Adjuvant Setting For EGFR +VE Patiens – Yes – CLCCO 2015

@OncEd Presents Dr. Paris Ingledew – Debate: Prophylactic Brain radiation For Extensive Stage Small Cell Cancer – Yes – CLCCO 2015

@OncEd Presents Dr. Patrick Cheung – Debate: Prophylactic Brain radiation For Extensive Stage Small Cell Cancer – No – CLCCO 2015

@OncEd Presents Dr. Charles Butts – Debate: Targeted Therapy Vs. Immunotherapy For First Line In SNCLC – NO – CLCCO 2015

@OncEd Presents Dr. Normand Blais – Debate: Targeted Therapy VS. Immunotherapy For First Line In NSCLC – YES – CLCCO 2015

@OncEd Presents Dr. Ross Camidge – The Changing World of Alk Mutations and Treatment – Lung Cancer – CLCCO 2015

@OncEd Presents Dr. Robert Kerbel – Anti-Angiogenic Therapies In Cancer – 2015

@OncEd Presents Dr. Alexander Lyon – Proteasome Inhibition – GCOS 2015

@OncEd Presents Dr. Lee Jones – Impairments In Cardiovascular Reserve Capacity And Efficacy of Exercise Countermeasures In Cancer – GCOS 2015

@OncEd Presents Dr. Michael Fradley – QT Prolongation And Other Electrophysiologic Considerations In Cancer Patients Undergoing Stem Cell therapy – GCOS 2015

@OncEd Presents Dr. Giorgio Minotti – Developing a Dedicated Cardio-Oncology Journal – GCOS 2015

@OncEd Presents Dr. Zaza Iakobishvili – Can Cardio-Oncology Deliver Improved Practice Internationally – GCOS 2015

@OncEd Presents Dr.Susan Dent – Establishing a Cardio-Oncology Clinic – GCOS 2015

@OncEd Presents Dr. Paul Richardson – Contemporary Treatment of Multiple Myeloma – GCOS 2015

@OncEd Presents Dr. Daniela Cardinale – The Practical Use of Cardiac Biomarkers – GCOS 2015

@OncEd Presents Dr. Ronald Schwartz – Leading Lessons of Radionuclide Angiocardiography – GCOS 2015

@OncEd Presents Dr. Anju Nohria – Autonomic Dysfunction in Patients Treated With Mediastinal or Neck Radiation – GCOS 2015

@OncEd Presents Dr. Dinesh Thavendiranathan – The Use of Strain And Newer Echocardiography Imaging Techniques – GCOS 2015

@OncEd Presents Dr. Sebastian Szmit – Is Dasatinib-Related Pulmonary Hypertension a Concern – GCOS 2015

@OncEd Presents Dr. Michael Savona – A Revolution in the treatment of Leukemia – GCOS 2015

@OncEd Presents Dr. Kathleen Pritchard – Comprehensive Cancer Care Includes Addressing Potential Impact of Cardiovascular Toxicity – GCOS 2015

@OncEd Presents Dr. Stephen Chia & Dr. Hope Rugo – Controversies and Challenges in Management of Metastatic Breast Cancer – Breast Cancer – 2015

@OncEd Presents Dinner Symposium: Shaping the Standard of Care – Best of Lung Cancer – 2015

@OncEd Presents Dr. Ros Juergens – Lung Cancer Immunotherapy: The Landscape in Canada – Best of Lung Cancer 2015

@OncEd Presents Dr. Scott Laurie – Squamous Cell Lung Update – Best of Lung Cancer – 2015

@OncEd Presents Dr. Barb Melosky – New Targets in NSCLC – Best of Lung Cancer – 2015

@OncEd Presents Case Based Discussions: Locally Advanced Lung Cancer – Best of Lung Cancer – 2015

@OncEd Presents Dr. Jeff Rothenstein – Advances in Alk-Positive NSCLC – Best of Lung Cancer – 2015

@OncEd Presents Dr. Ron Burkes – Adjuvant Treatment In NSCLC – Best of Lung Cancer – 2015

@OncEd Presents Dr. Heidi Roberts – Screening Update – Best of Lung Cancer – 2015

@OncEd Presents Lunch Symposium: Mapping Better Outcomes in Advanced NSCLC – Best Of Lung Cancer – 2015

@OncEd Presents Panel Discussion – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Neil Berinstein – The Future Of Immuno-Oncology – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Marcus Butler – T-Cell Transfer Therapies – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Omid Hamid – Immunotherapy For Melanoma Patients – Best Of Immuno-Oncology – 2015

@OncEd Presents Dr. Natasha Leighl Immunotherapy in Lung Cancer – Best Of Immuno-Oncology 2015

@OncEd Presents Dr. Georg Bjarnason – Immuno-Oncology: Renal Cell – Best Of Immuno-Oncology 2015

@OncEd Presents Dr. Linh Nguyen – The Basic Premise of Immuno-Oncology – Best Of Immuno-Oncology

@OncEd Presents Panel Discussion: Workforce Planning in Oncology Across Canada – CAMO 2015

@OncEd Presents Dr. Jean Latreille – HR Planning in Oncology: Quebec – CAMO 2015

@OncEd Presents Dr. Leonard Kaizer – HR Planning in Oncology: Ontario – CAMO 2015

@OncEd Presents Dr. Chris Lee – HR Planning in Oncology: British Columbia – CAMO 2015

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Annie Young, SRN, PhD, Professor of Nursing, University of Warwick, Coventry, UK, discusses the clinical significance of chemotherapy-induced nausea and vomiting, which continues to greatly impact the quality of life of patients, and the role of oncology nurses in the management and education of patients undergoing potentially emetogenic therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal Marsden NHS Foundation Trust, London, UK, discusses an audit that was designed to evaluate the Acute Oncology Service nursing role across the London Cancer Alliance, which is a collaboration of 17 healthcare provider organisations in London, as well as determining their professional development needs. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

From our Ask the Expert series, MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance and the Fred Hutchinson Cancer Research Center responds to Patient Power community member Amandas question, Is there any research on pregnancy and essential thrombocythemia (ET)? What are my risks? Dr. Scott discusses both historical and anecdotal data, including safe treatments. Dr. Scott cautions patients, however, to be sure to consult an MPN expert both before and during pregnancy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From our Ask the Expert series, MPN expert Dr. Jamile Shammo, with Rush University Medical Center in Chicago, answers a question from Jane, What does it mean if you are JAK+ or CALR+, and how does it affect my treatment or prognosis? Dr. Shammo compares and contrasts these two mutations, offering insight based on clinical studies and registry data. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Martin Wiseman, MD talks about how the environment we live in determines the patterns of cancer across the world. There is now an increasingly large volume of data that supports that nutritional factors, not just diet but obesity and physical activity, that determine the body’s ability to fight cancer. After smoking, obesity and physical activity are the most important factors that can be used to prevent cancer.

@OncEd Presents Dr. Allan Covens – BRCA mutations in ovarian cancer

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the results of the Pomi-T clinical trial. The study focused on the effects of Pomi-T on prostate-specific antigen (PSA) levels in prostate cancer patients. He highlights the main results, such as the reduction of PSA levels, and other important factors that should be considered when taking food supplements.

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses non-medicinal strategies to help cancer patients cope with cancer therapy side-effects. Prof. Robert Thomas suggests changes in lifestyle, such as daily light exercise and a healthy and balanced diet.

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the importance of having a healthy diet for cancer patients. Prof. Robert Thomas suggests that cancer patients and the general community, should increase the intake of fruit and vegetables, rich in polyphenols. he then goes on to discuss the results of a double-blind, randomised clinical trial (Pomi-T), where the intake of whole-food supplements rich in polyphenols, showed to reduce the levels of prostate-specific antigen (PSA) and tumour size.